H.C. Wainwright initiated coverage on MetaVia with a new price target
$MTVA
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/4/2025 | $12.00 | Buy | H.C. Wainwright |
| 12/30/2024 | $12.00 | Buy | H.C. Wainwright |
H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00
H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00
CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that two abstracts highlighting data on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), have been accepted for poster presentations at ObesityWeek® 2025, taking place in-person and virtually November 4-7, 2025 in Atlanta, GA. Title: Safety, Tolerability, and Pharmacokinetics of DA-1726, an Oxyntomodu
CAMBRIDGE, Mass., Oct. 14, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that President and Chief Executive Officer, Hyung Heon Kim, will present a company overview at the H.C. Wainwright Liver Disease Virtual Conference taking place October 21-22, 2025. Mr. Kim and Marshall H. Woodworth, Chief Financial Officer, will also participate in one-on-one meetings. Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting
CAMBRIDGE, Mass., Aug. 26, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced its participation in upcoming investor and industry conferences. September 3-5: Wells Fargo Healthcare Conference. Hyung Heon Kim, President and Chief Executive Officer will attend this conference in Boston, Massachusetts.September 8-10: H.C. Wainwright 27th Annual Global Investment Conference. Mr. Kim will participate in fireside chat. The Company's on-demand presentation will be available to view
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
SCHEDULE 13G/A - MetaVia Inc. (0001638287) (Subject)
8-K - MetaVia Inc. (0001638287) (Filer)
10-Q - MetaVia Inc. (0001638287) (Filer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)